Tag: TMVI

TMVI in inoperable patients is feasible but mortality high at one...

One-year outcome data for transcatheter mitral valve implantation (TMVI), in inoperable patients, indicate most patients who survive the first 30 days after the procedure...

ICI 2017: Novel transcatheter mitral valve wins Best Technology Parade Presentation

4C Medical Technologies has won the Best Technology Parade Presentation award—at  the 2017 Innovations in Cardiovascular Interventions (ICI) meeting (3–5 December, Tel Aviv, Israel)—for...

TCT 2017: TMVI in mitral ring is a reasonable alternative for...

Data from the MITRAL (Mitral Implantation of Transcatheter valves) study indicate that transeptal transcatheter mitral valve implantation (TMVI), with a Sapien 3 device (Edwards...

TCT 2017: Two studies support feasibility of transcatheter mitral valve implantation

Early experiences with two transcatheter mitral valve implantation (TMVI) devices—Intrepid (Medtronic) and the Tendyne mitral valve (Abbott)—indicate that TMVI may be a safe and...

First patient implanted with Intrepid TMVI device in APOLLO trial

The first patient in the APOLLO trial has undergone transcatheter mitral valve implantation (TMVI) with the Intrepid device (Medtronic). The study—the first-ever pivotal trial...

Neovasc provides Tiara clinical update

Neovasc has provided an update on the study progress and clinical performance of the Tiara valve, a self-expanding mitral bioprosthesis for transcatheter implantation in...

Novel mitral regurgitation therapy featured in Innovation Summit at Cardiovascular Innovations

4C Medical Technologies has announced that its medical device therapy for mitral regurgitation was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017...

LivaNova acquires Caisson Interventional

LivaNova has announced it has acquired the remaining outstanding interests in Caisson Interventional in support of its strategic growth initiatives. Based in Maple Grove...

Neovasc receives approval to launch European study of Tiara transcatheter mitral...

Neovasc has received both regulatory and ethics committee approval to initiate the Tiara transcatheter mitral valve replacement study (TIARA II) in Italy. The study...

TCT 2016: Tiara TMVI device highlighted in presentations

Neovasc has announced today its notable presentations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA). On 31 October,...

First-in-human implants of Caisson Interventional’s percutaneous mitral valve device performed

Caisson Interventional has announced the first successful human implants of its fully percutaneous, transvascular mitral valve implant, which is designed as a functional replacement in...

TMVI: What we know

Transcatheter mitral valve implantation (TMVI) is being explored as an approach to managing patients with mitral regurgitation who cannot undergo surgery. In this PCR,...

FDA gives Neovasc go-ahead to add 40mm valve size to its...

The FDA has given Neovasc approval for participating physicians to treat patients with the company’s 40mm Tiara valve in its TIARA-I early feasibility trial. The...